In order to further resolve the genetic architecture of the inflammatory bowel diseases, ulcerative 10 colitis and Crohn's disease, we sequenced the whole genomes of 4,280 patients at low coverage, 11 and compared them to 3,652 previously sequenced population controls across 73.5 million 12 variants. To increase power we imputed from these sequences into new and existing GWAS 13 cohorts, and tested for association at ~12 million variants in a total of 16,432 cases and 18,843 14 controls. We discovered a 0.6% frequency missense variant in ADCY7 that doubles risk of 15 ulcerative colitis, and offers insight into a new aspect of disease biology. Despite good statistical 16 power, we did not identify any other new low-frequency risk variants, and found that such variants 17 as a class explained little heritability. We did detect a burden of very rare, damaging missense 18 variants in known Crohn's disease risk genes, suggesting that more comprehensive sequencing 19 studies will continue to improve our understanding of the biology of complex diseases. 20 21 42 GWAS loci 17 , and others have more generally observed 18 that the substantial majority of complex disease 43 associated variants lie in non-coding, presumed regulatory, regions of the genome. Low coverage whole 44 genome sequencing has been proposed 19 as an alternative approach that captures this important non-45 coding variation, while being cheap enough to enable thousands of individuals to be sequenced. As 46 expected, this approach has proven valuable in exploring rarer variants than those accessible in 47 Results 56 Whole genome sequencing of 8,354 individuals 57
Introduction

22
Crohn's disease and ulcerative colitis, the two common forms of inflammatory bowel disease (IBD), are 23 chronic and debilitating diseases of the gastrointestinal tract that result from the interaction of 24 environmental factors, including the intestinal microbiota, with the host immune system in genetically 25 susceptible individuals. Genome-wide association studies (GWAS) have identified 210 IBD associated loci that have substantially expanded our understanding of the biology underlying these diseases [1] [2] [3] [4] [5] [6] [7] . The 27 correlation between nearby common variants in human populations underpins the success of the GWAS 28 approach, but this also makes it difficult to infer precisely which variant is causal, the molecular 29 consequence of that variant, and often even which gene is perturbed. Rare variants, which plausibly have 30 larger effect sizes, can be more straightforward to interpret mechanistically because they are correlated 31 with fewer nearby variants. However, it remains to be seen how much of the heritability 8 of complex 32 diseases is explained by rare variants. Well powered studies of rare variation in IBD thus offer an 33 opportunity to better understand both the biological and genetic architecture of an exemplar complex 34 disease.
35
The marked drop in the cost of DNA sequencing has enabled rare variants to be captured at scale, but 36 there remains a fundamental design question regarding how to most effectively distribute short sequence 37 reads in two dimensions: across the genome, and across individuals. The most important determinant of 38 GWAS success has been the ability to analyze tens of thousands of individuals, and detecting rare 39 variant associations will require even larger sample sizes 9 . Early IBD sequencing studies concentrated on 40 the protein coding sequence in GWAS-implicated loci [10] [11] [12] [13] , which can be naturally extended to the entire 41 exome [14] [15] [16] . However, coding variation explains at most 20% of the common variant associations in IBD GWAS 20,21 , but is not ideally suited to the analysis of extremely rare variants.
48
Our aim was to determine whether low coverage whole genome sequencing provides an efficient means 49 of interrogating these low frequency variants, and how much they contribute to IBD susceptibility. We 50 present an analysis of the whole genome sequences of 4,280 IBD patients, and 3,652 population controls 51 sequenced as part of the UK10K project 22 , both via direct comparison of sequenced individuals and as 52 the basis for an imputation panel in an expanded UK IBD GWAS cohort. This study allows us to examine, 53 on a genome-wide scale, the role of low-frequency (0.1%≤ MAF < 5%) and rare (MAF < 0.1%) variants in 54 IBD risk (Figure  1 ).
associations. However, even this stringent quality control could not eliminate all false positives: we saw 85 extremely significant p-values at many SNPs outside of known loci (e.g. ~7,000 with p < 10 -15 ), 95% of 86 which had an allele frequency below 5% (Supplementary Figure  5 ). While we estimate that this analysis 87 produced well calibrated association test statistics for more than 99% of sites, the heterogeneity of our 88 sequencing depths makes it challenging to differentiate between false-positives driven by remaining 89 artifacts and true low-frequency associations. 
164
For each of 18,670 genes, we tested for a differential burden of rare (MAF < 0.5%, excluding singletons) 165 functional or predicted damaging coding variation in our sequenced cases and controls (Online Methods, 166 Supplementary  Table  6 ). We detected a significant burden of damaging rare variants in the well-known 167 Crohn's disease risk gene NOD2 (P functional = 1x10 −7 , Supplementary  Figure  9 ), which was independent of 168 the known low-frequency NOD2 risk variants (Online Methods). We noted that the additional variants 169 ( Figure  4 ) that contribute to this signal explain only 0.13% of the variance in disease liability, compared to 7 1.15% for the previously known variants 10 , underscoring the fact that very rare variants cannot account for 171 much population variability in risk.
confidently implicated in IBD risk by fine-mapping or functional data, and (ii) 63 additional genes 175 highlighted by less precise GWAS annotations (Supplementary Methods, Supplementary  Table  9 ). We 176 tested these two sets (after excluding NOD2, which otherwise dominates the test) using an enrichment 177 procedure 41 that allows for differing direction of effect between the constituent genes (Supplementary 178 Methods). We found a burden in the twelve confidently implicated Crohn's disease genes that contained 179 at least one damaging missense variant (P damaging = 0.0045). By contrast, we saw no signal in the second, 180 more generic set of genes (P=0.94, Figure  5 , Table  1 ).
181
We extended this approach to evaluate rare regulatory variation, using enhancer regions described by the 182 FANTOM5 project. Within each robustly defined enhancer 43 , we tested all observed rare variants, as well 183 as the subset predicted to disrupt or create a transcription factor binding motif 17 . We combined groups of 184 enhancers with cell- and/or tissue-type specific expression, in order to improve power in an analogous 185 fashion to the gene set tests above. However, none of these tissue or cell specific enhancer sets had a 186 significant burden of rare variation after correction for multiple testing ( Supplementary  Table  13 
200
We have participated in one such example of a powerful joint analysis by contributing our WGS data to 201 the Haplotype Reference Consortium 26 , which has collected WGS data from more than 32,000 individuals 202 into a reference panel that allows accurate imputation down to 0.1% allele frequency. Indeed, one might 203 question the value of generating our own IBD-enriched imputation panel for the analyses described here, 204 when a public resource will eventually offer better accuracy in existing GWAS data. Ultimately, however, 205 most of the data in the Haplotype Reference Consortium comes from projects like ours, so individual 206 groups must balance investment in sequencing and waiting for development of public resources.
207
We discovered an association to a low frequency missense variant in ADCY7, which represents the 208 strongest ulcerative colitis risk allele outside of the major histocompatibility complex. The most 209 straightforward mechanistic interpretation of this association is that loss-of-function of ADCY7 reduces 210 production of cAMP, leading to an excessive inflammatory response that predisposes to IBD. Previous 211 evidence suggested that general cAMP-elevating agents that act on multiple adenylate cyclases might, in 212 fact, worsen IBD 45 . While members of the adenylate cyclase family have been considered potential 213 targets in other contexts 37 , specific upregulation of ADCY7 has not yet been attempted, raising the 214 intriguing possibility that altering cAMP signalling in a leukocyte-specific way might offer therapeutic 215 benefit in IBD.
216
Despite our study being specifically designed to interrogate both coding and non-coding variation, our 217 sole new association was a missense variant. This is perhaps unsurprising, as the only previously 218 identified IBD risk variants with similar frequencies and odds ratios are protein-altering changes to NOD2, 219 IL23R and CARD9. More generally, the alleles with largest effect sizes at any given frequency tend to be 220 coding 17 , and are therefore the first to be discovered when new technologies expand the frequency 221 spectrum of genetic association studies. This pattern is further reinforced by the tantalizing evidence we 222 found for a burden of very rare coding variants in previously implicated IBD genes. Future deep 223 sequencing studies (exomes or whole genomes), which have near complete power to detect such 224 variants, have the potential to reveal allelic series ranging from rare highly penetrant variants to common, 225 weak GWAS signals.
Nonetheless, it is likely that nearly all low-frequency IBD susceptibility alleles are regulatory, as is the 227 case for common risk variants, but their effect sizes are too modest to be detected by our current sample 228 size. The paucity of large effects at low frequency variants, modest additional heritability explained by 229 those variants, and the fact that rare variants can hardly ever explain a large fraction of population 230 variation in relatively common diseases, suggest a dichotomy where rare variant association studies are 231 more readily interpreted, but common variant association studies are better suited to discover new 232 biology for a given budget. The ADCY7 association offers a direct window on a new IBD mechanism, but 233 is a relatively meager return compared to the number of loci discovered more simply by increasing GWAS 234 sample size 31 . Together, our discoveries highlight a number of lessons of more general relevance beyond 235 IBD genetics and underline the fact that, while there is much to be learned, transitioning from GWAS to 236 WGS-based studies will not be straightforward.
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